Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies - Wikidata - wikimedia - TriplyDB

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies

http://www.wikidata.org/entity/Q21131216

about

The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications IgG4 Characteristics and Functions in Cancer Immunity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Antibody-drug conjugates as novel anti-cancer chemotherapeutics Innate immunity in disease Natural killer cell biology: an update and future directions Immunotherapy for colorectal cancer The Janus Face of Death Receptor Signaling during Tumor Immunoediting Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses.Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Carbamylation of immunoglobulin abrogates activation of the classical complement pathway.A novel M2e based flu vaccine formulation for dogs.Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles Influenza-Specific Antibody-Dependent Phagocytosis.Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.Precision glycocalyx editing as a strategy for cancer immunotherapy.Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.Natural killer cell receptors: alterations and therapeutic targeting in malignancies.New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

P2860

Q26747516-35836F84-A797-4B69-B8CB-5185A38F48A2 Q26770244-4EF7F0A0-E7AD-4D87-8C19-9086DD859705 Q26774678-6DEAC034-0EF5-4D2A-8181-965001960B30 Q26800175-63BD522B-232A-48A6-B53F-900E651F880B Q26825435-2FC4295F-E929-4307-987A-6EBBE2A45B23 Q26830512-839D7413-FAFB-4E87-A355-CA96C5A06A86 Q27021837-969DD63E-E07B-4A37-AC48-8F35EEA23388 Q28070036-3AF09F9D-0DEE-42E1-B0B7-075199F35A02 Q28071998-AE57A908-EE8A-4239-A09E-3650C657F5AB Q28081338-A580AA2D-399A-49FE-B0AC-2D7FDA64DE03 Q33632113-6CBCC0D3-1DC9-4A69-9A38-F8B705746A49 Q34169579-DD3961DC-7D98-4F09-ADD8-7654B82A0450 Q34223860-C6DA40E7-8B3A-4B58-AABA-960FFF7C8ECC Q34486159-48408A43-20B1-44C7-B0EA-E983D66F9D62 Q34516987-06D8D1A2-5BD2-4E28-A217-0265378B606B Q35009732-E1624033-C405-4C51-8EDC-69F76F440696 Q35639002-7E87313C-066C-4834-B098-8B1A1ABC1107 Q35653952-F8F9C73A-A080-448A-9DDA-E8F16936B472 Q36002107-83A463EB-34E7-4080-88D2-D9C0106FFCFB Q36055257-D1E20199-04DC-498C-B460-0847255F6E3A Q36544773-3304C36D-3510-4BC7-B7F4-D93B25C0A1A1 Q36751784-F80D05CA-38A0-40B1-BCD9-F1F357897973 Q37022365-49EF3BA6-1390-4B55-BA07-F69BAD554296 Q37130228-1961F011-3F9E-4EDA-8D3C-FB75629286B3 Q37171499-69C9C285-9BB1-41D4-AAD2-9E85609EF695 Q37264064-7DFD4421-4B4E-42A1-89A9-DDD4EEA27309 Q37473163-35093A21-93B9-48AE-8F04-CA92528926AE Q37537926-BA772C38-19B8-4562-B701-6826386B95B4 Q37575182-ED7CECA4-1511-4781-A27D-768AE24A2E47 Q37689046-127FEB13-33EA-4BCD-99F4-DD4DF6E75619 Q38148501-6A3E29CB-78BC-4C1A-A7CF-0ED03B50CEC6 Q38408253-3C8577D0-09F5-4E1E-AE38-BD1A9D9105DB Q38542034-3E89B376-9DBC-468F-A7B0-53D077B5D4A9 Q38563897-CFCBED56-4F01-4B11-8AF9-962372DB6340 Q38587627-734EEB49-A561-4FA1-86ED-A89F85577D50 Q38648979-B259BC4D-B3A4-4D7C-9C1C-4793B03E6106 Q38759754-F28FB3A7-0A8A-44FC-9CFB-509471837C9D Q38780121-C62F70E0-FC53-4197-B8B2-1980E069158A Q38849985-3DEBCEDC-6B57-4D28-834E-B872A79E6912 Q38861743-680EC4C7-2AEB-4EF4-9316-4302F196F7E8

P2860

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies

http://www.wikidata.org/entity/Q21131216

description

2013 nî lūn-bûn

@nan

2013 թուականին հրատարակուած գիտական յօդուած

@hyw

2013 թվականին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Natural killer cell mediated a ...... py with therapeutic antibodies

@ast

Natural killer cell mediated a ...... py with therapeutic antibodies

@en

Natural killer cell mediated a ...... py with therapeutic antibodies

@en-gb

Natural killer cell mediated a ...... py with therapeutic antibodies

@nl

type

label

Natural killer cell mediated a ...... py with therapeutic antibodies

@ast

Natural killer cell mediated a ...... py with therapeutic antibodies

@en

Natural killer cell mediated a ...... py with therapeutic antibodies

@en-gb

Natural killer cell mediated a ...... py with therapeutic antibodies

@nl

altLabel

Natural Killer Cell Mediated A ...... py with Therapeutic Antibodies

@en

prefLabel

Natural killer cell mediated a ...... py with therapeutic antibodies

@ast

Natural killer cell mediated a ...... py with therapeutic antibodies

@en

Natural killer cell mediated a ...... py with therapeutic antibodies

@en-gb

Natural killer cell mediated a ...... py with therapeutic antibodies

@nl

P1433

Q21131216-C8554FB4-4B8B-4D7B-82AA-94A5AFB7616A

P1476

Q21131216-DF63CFFB-70F0-426F-BB24-65DAABF02FE2

P2093

Q21131216-36869C96-9E70-4FA5-966F-20EDB80C069D

Q21131216-64F94468-EB61-4AE8-8EE8-7FCEBC19468C

Q21131216-D3F24578-19A4-4603-A9E7-1B6E606830BF

P2860

Q21131216-055C971E-8D07-4910-B480-66874BF88435

Q21131216-05FA995A-9A53-495F-994B-44E9FAF554C3

Q21131216-08950F0A-F1C5-4DF9-A5B2-8FDE7279BABA

Q21131216-0C232B3E-692C-4BA8-94BD-295D13606131

Q21131216-0C4DCDA5-7257-41D2-814B-4A0067CE0D8F

Q21131216-0DA2C1E4-8B4C-4202-B4F3-1FD217A0D928

Q21131216-14B0515D-F837-48D3-AEAA-C7720796D86A

Q21131216-15D49B00-A8F7-4A36-B73F-332EB22AD986

Q21131216-1607FE2B-1FC6-4F64-A831-AD6309DC07D6

Q21131216-1C273EE6-A44E-42F6-95FF-AE3E139E8DA1

P304

Q21131216-9736BCD9-E9EA-4FB6-B869-E6FFEE88CD42

P31

Q21131216-05891F05-8104-4511-95D3-5559D54183F1

P3181

Q21131216-3A57EC36-3AD7-4E68-B752-07150D256934

P356

Q21131216-D740CBCF-FE40-4520-95D6-92F35D2CFD27

P407

Q21131216-817490ED-1F46-440A-93E0-7B177C1D84CC

P478

Q21131216-9B7E4E44-7153-416F-89CD-48744A2055F3

P577

Q21131216-5A8C7E2B-744A-41BD-86E1-05E9520F1E71

P5875

Q21131216-63D79C33-4B7B-4643-A559-522BCFCD2C2B

P698

Q21131216-E4363848-1824-42D8-A961-26EDFFC04E6A

P921

Q21131216-D8EFD26F-5EA2-4A34-A8A4-26A2FAE12278

Q21131216-E195F6BF-F353-4292-BC00-E31C367C74B4

Q21131216-F9B05E14-88D9-4739-88C6-17700764C628

P932

Q21131216-143CF0AD-FA19-4F90-8D43-07CDC0A3F36D

P3181

P356

FIMMU.2013.00076

P1433

Frontiers in Immunology

P1476

Natural killer cell mediated a ...... py with therapeutic antibodies

@en

P2093

Patrick Schlegel

http://www.w3.org/2001/XMLSchema#string

Peter Lang

http://www.w3.org/2001/XMLSchema#string

Ursula J E Seidel

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Antibody therapy of cancer

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Innate or adaptive immunity? The example of natural killer cells

Fcgamma receptors as regulators of immune responses

Trastuzumab--mechanism of action and use in clinical practice

Up on the tightrope: natural killer cell activation and inhibition

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

P304

76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

691822

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FIMMU.2013.00076

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236094997

http://www.w3.org/2001/XMLSchema#string

P698

23543707

http://www.w3.org/2001/XMLSchema#string

P921

P932

3608903

http://www.w3.org/2001/XMLSchema#string